Concurrent chemoradiotherapy with tomotherapy in locally advanced non-small cell lung cancer: A phase i, docetaxel dose-escalation study, with hypofractionated radiation regimen

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Bearz, Alessandra ^a   Minatel, Emilio ^a   Rumeileh, Imad A ^a   Borsatti, Eugenio ^a   Talamini, Renato ^a   Franchin, Giovanni ^a   Gobitti, Carlo ^a   Del Conte, Alessandro ^b   Trovò, Marco ^a   Baresic, Tanja ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b GENERAL HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE ESCALATION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG FUNCTION TEST; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RADIATION DOSE ESCALATION; THROMBOCYTOPENIA; TOMOTHERAPY; TREATMENT PLANNING; TUMOR CELL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TAXOIDS; TREATMENT OUTCOME;

EID: 84887100837     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-513     Document Type: Article

References (29)

1. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2181-2190. 10.1200/JCO.2009.26.2543, 20351327.
2. Vokes EE, Herndon JE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007, 25:1698-1704. 10.1200/JCO.2006.07.3569, 17404369.
3. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008, 26:5755-5760. 10.1200/JCO.2008.17.7840, 19001323.
4. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline:update 2003. J Clin Oncol 2004, 22:330-353.
5. Van Meerbeeck JP, Kramer GW, Van Schil PE, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer. J Natl Cancer Inst 2007, 99:442-450. 10.1093/jnci/djk093, 17374834.
6. Gandara DR, Chansky K, Albain KS, et al. Southwest Oncology Group Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003, 21:2004-2010. 10.1200/JCO.2003.04.197, 12743155, Southwest Oncology Group.
7. Mason KA, Kishi K, Hunter N, et al. Effect of docetaxel on the therapeutic radio of fractionated radiotherapy in vivo. Clin Cancer Res 1999, 5:4191-4198.
8. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003, 21:1752-1759. 10.1200/JCO.2003.11.040, 12721251.
9. Scagliotti GA, Szczesna A, Ramlau R, et al. Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small cell lung cancer. Br J Cancer 2006, 94:1375-1382. 10.1038/sj.bjc.6603115, 2361263, 16641904.
10. Rosenzweig KE, Amols H, Ling CC. New radiotherapy technologies. Semin Surg Oncol 2003, 21:190-195. 10.1002/ssu.10037, 14508852.
11. Scrimger RA, Tome WA, Olivera GH, et al. Reduction in radiation dose to lung and other normal tissues using helical tomotherapy to treat lung cancer, in comparison to conventional field arrangements. Am J Clin Oncol 2003, 26:70-78. 10.1097/00000421-200302000-00014, 12576928.
12. Mackie TR, Holmes RW, Swedloll S, et al. Tomotherapy: a new concept for delivery of conformal radiotherapy. Med Phys 1993, 20:1709-1719. 10.1118/1.596958, 8309444.
13. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small cell lung cancer: CALBG 30105. J Clin Oncol 2008, 26:2457-2463. 10.1200/JCO.2007.14.7371, 18487565.
14. Salama JK, Stinchkombe TE, Gu L, et al. Pulmonary toxicity in stage III Non-Small Cell Lung Cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of cancer and leukaemia group B (CALBG) trial 30105. Int J Radiation Oncology Biol Phys 2011, 4:269-274.
15. Von Hoff DD, Kuhn J, Clark GM. Design and conduct of phase I trials. Cancer Clinical Trials - Methods and Practice 1990, 210-219. Oxford: Oxford Medical Publications, Buyse ME, Staquet MJ, Sylvester RJ, Part IV, n. 13.
16. Mauer AM, Masters GA, Haraf DJ, et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 1998, 16:159-164.
17. National Cancer Institute Common Terminology Criteria for adverse events (version 3.0)
18. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982, 8:1981-1987. 10.1016/0360-3016(82)90459-X, 6759484.
19. Steel G, Deacon J, Duchesne GM, et al. The dose-rate effect in human tumour cells. Radiother Oncol 1987, 9:299-310. 10.1016/S0167-8140(87)80151-2, 3317524.
20. Fowler JF. How worthwhile are short schedules in radiotherapy? A series of exploratory calculations. Radiother Oncol 1990, 18:165-181. 10.1016/0167-8140(90)90142-J, 2367691.
21. Mehta M, Scrimger R, Mackie R, Paliwal B, Chappell R, Fowler J. A new approach to dose escalation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001, 49(1):23-33. 10.1016/S0360-3016(00)01374-2, 11163494.
22. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guidelines (version1.1). Eur J Can 2009, 45:228-247.
23. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
24. Hainsworth JD, Burris HA, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 1998, 16:2164-2168.
25. Park J, Ahn YC, Kim H, et al. A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers. Lung Cancer 2003, 42:227-235. 10.1016/S0169-5002(03)00282-4, 14568691.
26. Belani CP, Choy H, Bonanni P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multimodality protocol. J Clin Oncol 2005, 23:5883-5891. 10.1200/JCO.2005.55.405, 16087941.
27. Birim O, Kappetein AP, Stijnen T, et al. Meta-analysis of positron-emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in non small cell lung cancer. Ann Thorac Surg 2005, 79:375-382. 10.1016/j.athoracsur.2004.06.041, 15620991.
28. De Langen AJ, Raijmakers P, Riphagen I, et al. The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg 2006, 29:26-29. 10.1016/j.ejcts.2005.10.002, 16337397.
29. Bral S, Duchateau M, Versmessen H, et al. Toxicity report of a phase 1-Feb dose-escalation study in patients with inoperable, locally advanced nonsmall cell lung cancer with helical tomotherapy and concurrent chemotherapy. Cancer 2010, 116:241-250.